Additional mechanisms that may explain the inverse expression between MYC and LMO2 may be related to the deregulation of E2A/TCF3 in Burkitt lymphoma or BCL2/BCL6 in DLBCL with MYCr or may perhaps be the result of the normal downregulation of LMO2 mRNA in the DZ of the germinal center in lymphomas that arise in the DZ and show a DZ signature [30,31]. The gene discussed is BCL2; the disease is Burkitt lymphoma.